Author: Berrichi, Samia; Bouayed, Zakaria; Benbouchta, Karima; Kossir, Amine; Bkiyar, Houssam; Ismaili, Nabila; Ouafi, Noha El; Housni, Brahim
Title: Incidental diagnosis of a large cardiac thrombus swinging through an interatrial communication in a COVID-19 patient: Case report and literature review Cord-id: g8mrpiiv Document date: 2021_10_19
ID: g8mrpiiv
Snippet: INTRODUCTION: The hypercoagulability state induced by COVID-19 has been well established and various forms of subsequent thromboembolic events have been reported throughout literature including multiple cases of intracardiac thrombi, four of which in our center alone, this case being the fifth. CASE REPORT: We report the case of a 38-year-old male with no prior cardiovascular history who -subsequently to a COVID-19 infection-developped a right atrial thrombosis associated to a pulmonary embolism
Document: INTRODUCTION: The hypercoagulability state induced by COVID-19 has been well established and various forms of subsequent thromboembolic events have been reported throughout literature including multiple cases of intracardiac thrombi, four of which in our center alone, this case being the fifth. CASE REPORT: We report the case of a 38-year-old male with no prior cardiovascular history who -subsequently to a COVID-19 infection-developped a right atrial thrombosis associated to a pulmonary embolism, and in whom cardiography revealed an interatrial communication. Management relied upon curative doses of low molecular weight heparin (LMWH) with favourable outcome. DISCUSSION: In our discussion, we lay out the various physiopathological mechanisms incriminated throughout literature in the genesis of a hypercoagulability state distinctive of COVID-19, before highlighting the incidence of an interatrial communication (whether a Potent Foramen Ovale or Atrial Septal Defect) discovered in patients with COVID-19, and the potential paradoxical embolization risks they imply as well as reported cases. A mention of hemostatic parameters monitored was also warranted. Finally we discuss the guidelines in terms of prophylactic and therapeutic anticoagulation in hospitalized patients before discussing cardiac thrombosis's therapeutic options. CONCLUSION: Our case highlights various key points which could change the prognosis of COVID-19 patients, whether related to the underdiagnosis of interatrial abnormalities or with regards to the diagnosis to thromboembolic events, but also the indisputable place of anticoagulation in COVID-19 management.
Search related documents:
Co phrase search for related documents- acute respiratory distress and lmwh low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute respiratory distress and lmwh molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute respiratory distress and low lmwh molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute respiratory distress and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- acute respiratory distress and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress management and adequate management: 1, 2, 3, 4
- acute respiratory distress management and lmwh low molecular weight heparin: 1
- acute respiratory distress management and lmwh molecular weight heparin: 1
- acute respiratory distress management and low lmwh molecular weight heparin: 1
- acute respiratory distress management and low molecular weight: 1
- acute respiratory distress management and low molecular weight heparin: 1
- lmwh low molecular weight heparin and low lmwh molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- lmwh low molecular weight heparin and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- lmwh low molecular weight heparin and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- lmwh low molecular weight heparin and macrophage activation: 1
- lmwh molecular weight heparin and low lmwh molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- lmwh molecular weight heparin and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- lmwh molecular weight heparin and macrophage activation: 1
Co phrase search for related documents, hyperlinks ordered by date